These engineered TRAC-encoded CD19 CAR T cells exhibited increased anti-tumor activities in the leukemic mouse model regarding the responses and prolonged medium survival compared to the conventional, randomly integrated CD19 CAR T cells. This evidence concerns the gene CD19 and neoplasm.